Existing user? Login

NICE recommendation means more people take atorvastatin to prevent heart disease

After changes to NICE guidelines, atorvastatin is likely to become the most prescribed drug in the UK



New NICE guidelines recommend an extra 4.5 million people in England take statins to prevent cardiovascular disease

Atorvastatin is set to become the most prescribed drug in the UK following changes to cardiovascular disease (CVD) prevention guidelines from the National Institute for Health and Care Excellence (NICE).

The recommend that all patients with a 10% or greater risk of developing CVD over the next ten years should be offered atorvastatin 20mg for primary prevention. This cuts the threshold by half, making an extra 4.5 million patients in England eligible for statins.

GPs will use a cardiovascular risk assessment tool, known as QRISK2, to assess the risk of patients.

Some 7 million people in the UK are taking a statin, costing the NHS £150m each year. Based on 80% patient compliance, NICE estimates that the increased use of statins, offset by the reduction in costs associated with cardiovascular events, would cost the NHS an additional £52m each year.

Atorvastatin is already seeing growth in volume terms. In 2013, it accounted for 18.2m prescription items dispensed in England, while competing product, simvastatin, sat at 39.9m items — being the most dispensed drug in England. However, atorvastatin’s volumes have risen by 6m items compared with 2012, following the expiry of its patent, while simvastatin items fell by 3m from the 42.6m million peak in 2012.

Graph on the reduction in low-density lipoprotein cholesterol and atorvastatin versus simvastatin

The guidelines also recommend that patients being treated for CVD should be offered the higher dose of 80mg atorvastatin. Patients who are stable on a low- or middle-intensity statin (see ‘Reduction in low-density lipoprotein cholesterol’) should discuss the benefits of switching to a high-intensity statin when they have a medication review, it adds.

Although the guidelines increase the number of patients eligible for statins, it does not mean all patients should receive them, stressed Mark Baker, director of the centre for clinical practice at NICE. “The guidance recognises the importance of choice in preventing CVD and that this should be guided by information on the trade-off between risks and benefits.”

However, the “weight of evidence clearly shows statins are safe, and clinically and cost-effective,” Baker added.

The new guidance could mean better discussions with patients, said Helen Williams, consultant pharmacist for cardiovascular disease for south London. “The guidance says to offer a statin — which implies a conversation. And that means the patient should be empowered.”

The guidance also recommends that all patients with CVD or at high-risk of CVD should eat a diet in which fat intake is 30% or less of total energy intake, and perform at least 150 minutes of moderate-intensity exercise or 75 minutes of vigorous aerobic activity each week.

In 2010 around 180,000 patients died of CVD in England and Wales and the condition cost the NHS in England around £7.9bn.

Citation: Electronicjuice DOI: 10.1211/PJ.2014.20065879

Readers' comments (1)

  • Rosuvastatin 10mg daily is most effective,but it is important not to miss doses..
    Atorvastatin 20mg. daily is of equal effectiveness, but is more likely to have adverse effects.

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

  • Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

  • English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Electronicjuice of Great Britain.

  • Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Supplementary images

  • Graph on the reduction in low-density lipoprotein cholesterol and atorvastatin versus simvastatin

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts. channel/6

тадалафил варденафил